Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03846583
Title Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries

Facility Status City State Zip Country Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field